Ran Fei
Impact in
- Hepatology top 5%
- Hepatitis C virus research
- Immunology top 5%
- Immune cells in cancer
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- interferon and immune responses
Papers in
- Hepatology 32
- Hepatitis C virus research 19
- Liver physiology and pathology 12
- Epidemiology 31
- Hepatitis B Virus Studies 21
- Liver Disease Diagnosis and Treatment 16
Ran Fei
83 papers receiving 1.4k citations
Hit Papers
Peers
Comparison fields: 5 of 110
- Hepatology 284
- Immunology 458
- Pharmacology 93
- Oncology 259
- Biochemistry 55
Countries citing papers authored by Ran Fei
This map shows the geographic impact of Ran Fei's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ran Fei with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ran Fei more than expected).
Fields of papers citing papers by Ran Fei
This network shows the impact of papers produced by Ran Fei. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ran Fei. The network helps show where Ran Fei may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Ran Fei, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 2 | |
| 2 | 2024 | 1 | |
| 3 | 2024 | 3 | |
| 4 | 2023 | 1 | |
| 5 | 2023 | 7 | |
| 6 | 2022 | 15 | |
| 7 | 2020 | 19 | |
| 8 | 2020 | 4 | |
| 9 | New progress in the pharmacology of protocatechuic acid: A compound ingested in daily foods and herbs frequently and heavily Hit paper breakdown → | 2020 | 211 |
| 10 | 2019 | 90 | |
| 11 | 2019 | 19 | |
| 12 | 2017 | 4 | |
| 13 | 2016 | 25 | |
| 14 | 2013 | 6 | |
| 15 | [Correlation between interleukin-28B genetic polymorphisms and primary hepatocellular carcinoma]. | 2012 | 5 |
| 16 | 2009 | 24 | |
| 17 | 2009 | 35 | |
| 18 | 2007 | 13 | |
| 19 | 2007 | 9 | |
| 20 | 2007 | 15 |
About Ran Fei
Ran Fei is a scholar working on Hepatology, Epidemiology, Immunology, Pharmacology and Oncology, having authored 85 papers that have together received 1.4k indexed citations. Recurring topics across this work include Hepatitis B Virus Studies (21 papers), Hepatitis C virus research (19 papers), Liver Disease Diagnosis and Treatment (16 papers), Liver physiology and pathology (12 papers), Immunotherapy and Immune Responses (9 papers), Immune Cell Function and Interaction (7 papers), Organ Transplantation Techniques and Outcomes (5 papers) and Cancer Immunotherapy and Biomarkers (5 papers). The work is most often cited by research in Hepatology (284 citations), Immunology (458 citations), Pharmacology (93 citations), Oncology (259 citations) and Biochemistry (55 citations). Ran Fei has collaborated with scholars based in China, United States and Singapore. Frequent co-authors include Lai Wei, Hongsong Chen, Xingwang Xie, Cong Xu, Dingkun Zhang, Henghui Zhang, Li Han, Chuanhong Luo, Feng Liu and Huiying Rao. Their work appears in journals such as Journal of Gastroenterology and Hepatology, Journal of Experimental & Clinical Cancer Research, Liver Transplantation, Clinical and Experimental Hypertension and Scientific Reports.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.